NYSE: CTLTCatalent Inc Stock
$53.61+0.03 (+0.06%)
Updated May 30, 2024
CTLT Price
$53.61
Fair Value Price
N/A
Market Cap
$9.70B
52 Week Low
$31.80
52 Week High
$60.20
P/E
-8.26x
P/B
2.69x
P/S
2.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.14B
Earnings
-$1.18B
Gross Margin
19%
Operating Margin
-24.11%
Profit Margin
-28.4%
Debt to Equity
1.74
Operating Cash Flow
$250M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTLT Overview
Catalent, Inc. provides manufactures branded drug products, biologics, gene therapies, and consumer health products. Catalent was formed in 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services segment of Cardinal Health, Inc. Catalent is headquartered in Somerset, NJ.
Zen Score
–
Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CTLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTLT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CTLT is poor value based on its book value relative to its share price (2.69x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.16x)
P/B vs Industry Valuation
CTLT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CTLT due diligence checks available for Premium users.
Be the first to know about important CTLT news, forecast changes, insider trades & much more!
CTLT News
Valuation
CTLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.26x
Industry
0.86x
Market
29.76x
CTLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.69x
Industry
2.16x
CTLT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTLT's financial health
Profit margin
Revenue
$1.1B
Net Income
-$101.0M
Profit Margin
-9.4%
CTLT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CTLT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9B
Liabilities
$6.3B
Debt to equity
1.74
CTLT's short-term assets ($2.52B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTLT's long-term liabilities ($5.26B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.0M
Investing
-$74.0M
Financing
$0.0
CTLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTLT vs Pharmaceutical Stocks
Catalent Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.